Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
|Articles|June 1, 2009
- ONCOLOGY Nurse Edition Vol 23 No 4
- Volume 23
- Issue 4
ONCOLOGY Nurse Edition April 2009, Vol 23 No 4
Advertisement
Main Articles
PALLIATIVE CARE SERIES: When Hospice Is the Best Option: An Opportunity to Redefine Goals
Reviewed in: Reviewed in: The Prince-Paul Article Reviewed: Improving the End-of-Life Experience
Departments
Patient Information
- Understanding and Managing Nausea and Vomiting
Articles in this issue
over 17 years ago
Hypertension Management in the Era of Targeted Therapies for Cancerover 17 years ago
An Alkylating Agent for CLL and NHLover 17 years ago
Vesicant Extravasation From an Implanted Venous Access Portover 17 years ago
Survivorship Care: Essential Components and Models of Deliveryover 17 years ago
Cardiotoxicities of Breast Cancer Treatmentover 17 years ago
Improving the End-of-Life Experienceover 17 years ago
When Hospice Is the Best Option: An Opportunity to Redefine Goalsover 17 years ago
Living Well: A Goal for All Patientsover 17 years ago
The Patient With Cancer-Related DyspneaAdvertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5